News Sentiment

LUCD sentiment intelligence

Lucid Diagnostics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 1.08 Week of 19 Jun 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

79/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+12.4% over one week, +0.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 79/100 classification
One-week reaction 12.4% Price confirming higher
Trend fit Trend inactive 0.9% over four weeks
Fair value -5.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 50
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 13
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
TradingView 4
PR Newswire 4
MSN 3
TradingKey 2
MarketBeat 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 37
Market update 19
Analyst action 3
Deals and strategy 2
Capital return 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
TradingKey Direct company coverage

Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a brief overview of Lucid Diagnostics Inc.'s (LUCD) revenue related to business segments and regions. It indicates that the company has not yet disclosed detailed financial data for business segments and most regional revenue contributions. Currently, the di

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 13:09
Source
TradingKey
TradingKey Direct company coverage

Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lucid Diagnostics Inc's (LUCD) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization ar

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:40
Source
TradingKey
www.marketscreener.com Direct company coverage

Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026.

Certain stock options of Lucid Diagnostics Inc. are currently subject to a lock-up agreement that concludes on June 9, 2026. This agreement restricts officers and directors from selling or disposing of common stock or convertible securities for a 45-day period, starting April 24,

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 00:09
Source
www.marketscreener.com
Insider Monkey Direct company coverage

Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results

Maxim Group reduced its price target on Lucid Diagnostics Inc. (NASDAQ:LUCD) from $3 to $2, while maintaining a Buy rating, following the company's weaker-than-expected first-quarter 2026 revenue report of $1.3 million. Despite the revenue miss and a GAAP net loss of $23.6 millio

Tone
Negative 38/100
Event
Earnings
Published
02 Jun 2026 14:05
Source
Insider Monkey
Finviz Direct company coverage

LUCD

This page provides a comprehensive overview of Lucid Diagnostics Inc. (LUCD) stock, including its latest financial metrics, performance indicators, and recent news. It details the company's stock price, market capitalization, insider ownership, and institutional holdings, alongsi

Tone
Neutral 50/100
Event
Market update
Published
31 May 2026 22:10
Source
Finviz
ChartMill Direct company coverage

LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD)

LUCID DIAGNOSTICS INC (NASDAQ:LUCD) shares are currently trading at $1.05, up 1.94% today. The company has experienced significant price decreases over the past month and year, but analysts expect a substantial price increase of nearly 300% in the next year, along with strong EPS

Tone
Neutral 50/100
Event
Earnings
Published
29 May 2026 14:09
Source
ChartMill
Stock Titan Direct company coverage

Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market

Lucid Diagnostics director, Dennis Matheis, purchased 245,000 shares of common stock on the open market at a weighted average price of $1.0011 per share. This transaction increases his direct ownership to 1,033,443 shares. The purchase, reported via a Form 4 SEC filing, indicates

Tone
Positive 74/100
Event
Market update
Published
21 May 2026 20:20
Source
Stock Titan
Insider Monkey Direct company coverage

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD) reported Q1 2026 earnings, missing expectations with an EPS of $-0.07. The company highlighted performing 3,177 EsoGuard tests, generating $1.3 million in revenue, and strengthening its balance sheet with $16.8 million in proceeds, extending i

Tone
Positive 60/100
Event
Earnings
Published
15 May 2026 12:10
Source
Insider Monkey
The Globe and Mail Direct company coverage

Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)

Canaccord Genuity analyst Kyle Mikson CFA has reiterated a Buy rating for Lucid Diagnostics (LUCD) with a price target of $3.00. The company recently reported a quarterly revenue of $1.5 million and a GAAP net loss of $16.27 million. Despite the loss, the analyst consensus mainta

Tone
Neutral 50/100
Event
Analyst action
Published
15 May 2026 11:10
Source
The Globe and Mail
TipRanks Direct company coverage

Lucid Diagnostics Earnings Call Balances Progress, Pressure

Lucid Diagnostics' Q1 earnings call revealed strong operational progress with EsoGuard test volumes exceeding pre-Medicare targets and an extended cash runway into 2027. However, the company faces significant challenges from slow reimbursement processes, volatile claim adjudicati

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 00:09
Source
TipRanks
TradingView Direct company coverage

Lucid Diagnostics 1Q 2026: Revenue $1.26M, EPS ($0.17) — 10-Q Summary

Lucid Diagnostics reported its first-quarter 2026 results, showing revenue of $1.26 million, a 51.7% increase from the prior year, and a reduced loss per share of ($0.17). The company attributed revenue growth to higher EsoGuard test volumes and expanded commercialization efforts

Tone
Positive 76/100
Event
Earnings
Published
14 May 2026 18:10
Source
TradingView
MSN Direct company coverage

Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates

Lucid Diagnostics Inc. (LUCD) announced its financial results for the first quarter, reporting a loss per share of $0.09. The company also registered revenue of $1.86 million, which fell short of analysts' expectations. This performance indicates a challenging quarter for Lucid D

Tone
Negative 19/100
Event
Earnings
Published
14 May 2026 16:08
Source
MSN
Investing.com Direct company coverage

Earnings call transcript: Lucid Diagnostics Q1 2026: Revenue Miss Despite EPS Match

Lucid Diagnostics (LUCD) reported Q1 2026 earnings, meeting EPS forecasts at -$0.07 but missing revenue expectations by 8.7% at $1.26 million. The revenue miss was attributed to a conservative revenue recognition policy within a transitional reimbursement environment. Despite the

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 14:08
Source
Investing.com
Stock Titan Direct company coverage

Cancer test firm ends Q1 with $45M as it targets Medicare coverage

Lucid Diagnostics reported Q1 2026 results, including $1.3 million in revenue and processing 3,177 EsoGuard tests, alongside a GAAP net loss of $23.6 million. The company strengthened its balance sheet with an equity offering that brought proforma cash to $45 million, extending i

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 12:08
Source
Stock Titan
PR Newswire Direct company coverage

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Lucid Diagnostics announced its first-quarter 2026 financial results, processing 3,177 EsoGuard tests and generating $1.3 million in revenue. The company ended the quarter with $45 million in proforma cash, extending its runway into 2027, and emphasized that securing Medicare cov

Tone
Positive 70/100
Event
Earnings
Published
14 May 2026 12:08
Source
PR Newswire
Stock Titan Direct company coverage

Lucid Diagnostics (NASDAQ: LUCD) narrows loss and extends cash runway into 2027

Lucid Diagnostics reported its Q1 2026 financial results, showing a GAAP net loss of $13.9 million and processing 3,177 EsoGuard tests, generating $1.3 million in revenue. The company successfully executed an underwritten public offering, netting $17 million, which extends its pr

Tone
Positive 65/100
Event
Earnings
Published
14 May 2026 12:08
Source
Stock Titan
TradingView Direct company coverage

LUCD: Q1 2026 saw higher revenue but continued losses, with future viability hinging on reimbursement and capital

Lucid Diagnostics Inc. (LUCD) reported increased revenue of $1.3M in Q1 2026, but also a net loss of $23.6M due to high costs. Despite boosting cash reserves to $27.9M with an April offering, the company's long-term survival is uncertain without more reimbursement options or addi

Tone
Negative 31/100
Event
Earnings
Published
13 May 2026 20:40
Source
TradingView
Stock Titan Direct company coverage

Lucid Diagnostics (NASDAQ: LUCD) grows Q1 revenue but flags going-concern risk

Lucid Diagnostics (NASDAQ: LUCD) reported increased Q1 2026 revenue of $1.3 million, up from $0.8 million year-over-year, driven by its EsoGuard test. However, the company continues to face significant financial challenges, posting a net loss of $23.6 million and disclosing "subs

Tone
Negative 29/100
Event
Earnings
Published
13 May 2026 20:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Lucid Diagnostics (Nasdaq:LUCD) - Stock Analysis

This report provides a comprehensive stock analysis of Lucid Diagnostics (Nasdaq:LUCD), a medical diagnostics technology company. It covers financial performance, future growth prospects, risks, and recent news, highlighting the company's EsoGuard Esophageal DNA Test for early ca

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 18:10
Source
Simply Wall Street
MSN Direct company coverage

Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates

Lucid Diagnostics Inc. (LUCD) reported a narrower-than-expected loss of 15 cents per share for the fourth quarter, surpassing the Zacks Consensus Estimate of a 19-cent loss. The company also beat revenue estimates, reporting $1.16 million compared to the anticipated $0.94 million

Tone
Neutral 50/100
Event
Earnings
Published
06 May 2026 04:39
Source
MSN